arrow
R

Roberta Lanzillo

University of Genoa
H指数:47
被引数:7,108

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gut microbiome profiling at multiple sclerosis onset as a potential early prognostic marker of disease course: evidence from an observational cohort

多发性硬化症发作时的肠道微生物组分析作为疾病进程的潜在早期预后标志物:来自一项观察性队列的证据

2026-09-010
OAAI
The impact of multiple sclerosis on social determinants of health: Results from the SocialMS study

多发性硬化对社会决定性健康因素的影响:SocialMS研究的结果

2026-07-010
OAAI
Dysarthria assessment in multiple sclerosis patients

多发性硬化患者的构音障碍评估

2025-12-190
PRE
Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis

血浆神经丝轻链在评估克拉屈滨治疗多发性硬化期间反应的应用

2025-12-040
OAAI
Anti-EBV antibody reduction during ocrelizumab treatment is not associated with multiple sclerosis outcomes

奥瑞利珠单抗治疗期间抗EBV抗体减少与多发性硬化结局无关联

2025-11-010
OAAI
Plasma Neurofilament Light Chain Is Associated with Cognitive Functions but Not Patient-Reported Outcomes in Multiple Sclerosis

血浆神经丝轻链与认知功能相关,但与多发性硬化患者报告结果无关。

2025-09-090
OA
A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis

一项多中心、前瞻性、随机、开放标签的实用试验,旨在比较干扰素β-1a和醋酸格列默在患有多发性硬化症的儿科患者中的有效性与安全性。

2025-08-080
OA
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis

年龄衍生截断值在多发性硬化血浆神经丝蛋白轻链中的临床应用

2025-07-090
PRE
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study

视神经脊髓炎谱系障碍中利妥昔单抗的长期有效性与安全性:一项5年观察性研究

2025-05-290
PRE
Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study

奥法美南(ocrelizumab)与那他珠单抗(natalizumab)在多发性硬化中的比较疗效、安全性与持续性:一项真实世界、多中心、倾向性评分匹配研究

2025-01-010
OAAI
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy

怀孕期间暴露于富马酸二甲酯的多发性硬化症妇女的意大利多中心队列的母婴结局

2024-09-120
PRE
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study

Ocrelizumab在阿仑单抗治疗后疾病活动持续存在的MS患者中: 一项多中心意大利研究

2024-08-140
PRE
Clinical utility of the Lumipulse™ immunoassay for plasma neurofilament light chain in multiple sclerosis
2024-08-010
OAAI
Clinical, prognostic and pathophysiological implications of MOG-IgG detection in the CSF: the importance of intrathecal MOG-IgG synthesis
2024-06-063
PRE
Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study

在多发性硬化症的不同治疗策略中使用Ocrelizumab: 一项基于人群的5年研究

2024-03-292
OAAI
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
2023-10-019
OAAI